1. Home
  2. FA vs ADPT Comparison

FA vs ADPT Comparison

Compare FA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Advantage Corporation

FA

First Advantage Corporation

HOLD

Current Price

$17.82

Market Cap

2.6B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$20.96

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FA
ADPT
Founded
2003
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
FA
ADPT
Price
$17.82
$20.96
Analyst Decision
Buy
Strong Buy
Analyst Count
4
9
Target Price
$15.67
$17.78
AVG Volume (30 Days)
1.8M
3.4M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
72.97
63.89
EPS
0.01
N/A
Revenue
$1,574,389,000.00
$276,976,000.00
Revenue This Year
$8.42
$3.98
Revenue Next Year
$7.26
$22.72
P/E Ratio
$1,676.00
N/A
Revenue Growth
83.02
54.77
52 Week Low
$8.82
$9.96
52 Week High
$18.55
$20.76

Technical Indicators

Market Signals
Indicator
FA
ADPT
Relative Strength Index (RSI) 66.92 71.02
Support Level $14.07 $15.08
Resistance Level N/A N/A
Average True Range (ATR) 0.72 1.33
MACD 0.02 0.28
Stochastic Oscillator 89.92 93.68

Price Performance

Historical Comparison
FA
ADPT

About FA First Advantage Corporation

First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: